Mildly oxidized low-density lipoproteins decrease early production of interleukin 2 and nuclear factor kappaB binding...

Area of Science:

• Immunology
• Cardiovascular Research
• Molecular Biology

Background:

• Activated T-lymphocytes are present in early atherosclerosis lesions.
• Oxidized low-density lipoproteins (oxLDLs) are implicated in atherosclerosis pathogenesis.
• Previous studies showed oxLDLs inhibit T-lymphocyte IL-2 receptor expression and proliferation.

Purpose of the Study:

• To investigate the effects of oxLDLs on T-lymphocyte blast differentiation, IL-2 synthesis, and NF-kappaB activation.
• To elucidate the mechanism by which oxLDLs influence T-lymphocyte activation in the context of atherosclerosis.

Main Methods:

• In vitro activation of T-lymphocytes using phytohaemagglutinin and PMA+ionomycin.
• Treatment of activated lymphocytes with varying concentrations of mildly oxLDLs.
• Measurement of lymphoblast numbers, IL-2 concentration, and NF-kappaB pathway activation (p65/p50 heterodimer binding, IkappaB-alpha levels).

Main Results:

• Mildly oxLDLs (50 and 100 µg/ml) reduced lymphoblast numbers and IL-2 production in culture supernatants.
• IL-2 production inhibition was observed in CD3(+) T-lymphocytes as early as 4 hours post-activation.
• oxLDLs decreased activation-induced p65/p50 NF-kappaB heterodimer binding to DNA, with no change in constitutive p50 or active IkappaB-alpha levels.

Conclusions:

• oxLDLs exert an immunosuppressive effect on T-lymphocytes.
• This immunosuppression may occur through dysregulation of T-lymphocyte activation pathways, specifically affecting NF-kappaB signaling.
• Findings suggest a novel mechanism for oxLDL involvement in atherosclerosis pathogenesis via immune modulation.